Acetic acid, [2-(4-morpholinyl)ethoxy]- | 127958-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Acetic acid, [2-(4-morpholinyl)ethoxy]-
• 英文别名: 2-(2-morpholin-4-ylethoxy)acetic acid
• CAS: 127958-77-4
• 化学式: C₈H₁₅NO₄
• 分子量: 189.21
• InChiKey: MJFUGZQQOLJOAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Compounds for enzyme inhibition
  申请人：Smyth S. Mark

  公开号：US20060030533A1

  公开（公告）日：2006-02-09

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  基于多肽的化合物，包括含有杂原子的三元环，能够高效且选择性地抑制N-末端亲核试剂(Ntn)水解酶的特定活性。这些具有多种活性的Ntn的活性可以通过所描述的化合物进行差异性抑制。例如，20S蛋白酶体的类似于胰蛋白酶的活性可以通过这些创新性的化合物进行选择性抑制。这些基于多肽的化合物包括环氧化物或氮杂环丙烷，并在N-末端进行了功能化。除了其他治疗用途外，这些基于多肽的化合物预计将表现出抗炎性和抑制细胞增殖的特性。
• [EN] COMPOUNDS FOR PROTEASOME ENZYME INHIBITION<br/>[FR] COMPOSES POUR L'INHIBITION ENZYMATIQUE DU PROTEASOME
  申请人：PROTEOLIX INC

  公开号：WO2006017842A1

  公开（公告）日：2006-02-16

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  肽基化合物包括含杂原子的三元环，能够高效且选择性地抑制N-末端亲核试剂（Ntn）水解酶的特定活性。这些具有多种活性的Ntn的活性可以被所描述的化合物差异性地抑制。例如，创蛋白酶样活性的20S蛋白酶可以通过这种创新的化合物被选择性地抑制。这些肽基化合物包括环氧化物或氮杂环，以及N-末端的官能化。除了其他治疗用途外，这些肽基化合物预计具有抗炎性和细胞增殖抑制作用。
• COMPOUNDS FOR PROTEASOME ENZYME INHIBITION
  申请人：Smyth Mark S.

  公开号：US20120329705A1

  公开（公告）日：2012-12-27

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  基于肽的化合物，包括含有杂原子的三元环，可以高效且选择性地抑制N-末端亲核基（Ntn）水解酶的特定活性。这些具有多种活性的Ntn的活性可以通过所描述的化合物进行差异性抑制。例如，20S蛋白酶体的胰凝乳样活性可以通过这种创新的化合物进行选择性抑制。这些基于肽的化合物包括环氧化物或氮杂环丙烷，以及N-末端的功能化。除了其他治疗用途外，这些基于肽的化合物预计将显示抗炎性和细胞增殖抑制作用。
• Compounds for proteasome enzyme inhibition
  申请人：Onyx Therapeutics, Inc.

  公开号：EP2270026B1

  公开（公告）日：2016-05-18
• Compounds for proteasome enzym inhibition
  申请人：Onyx Therapeutics, Inc.

  公开号：EP2266999B1

  公开（公告）日：2014-09-24